In a phase III study in renal cell carcinoma patients lapatinib displayed equivalent efficacy to hormone therapy treatment. Lapatinib prolonged overall survival relative to hormone therapy in patients with 3+ EGFR status determined by IHC.
Filed under: kinase | Tagged: EGFR, ErbB-2, ErbB2, GlaxoSmithKline, GSK, GSK-572016, GSK572016, HER2, kinase, Lapatinib, Tykerb, tyverb | Leave a Comment »
